13:00:24 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:MGTX from 2023-05-04 to 2024-05-03 - 17 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 16:30U:MGTXNews ReleaseMeiraGTx to Participate in Upcoming Investor Conferences
2024-04-18 16:30U:MGTXNews ReleaseMeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
2024-03-14 08:30U:MGTXNews ReleaseMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
2024-02-13 08:00U:MGTXNews ReleaseMeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
2023-12-21 07:00U:MGTXNews ReleaseMeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
2023-11-21 16:30U:MGTXNews ReleaseMeiraGTx to Participate in Upcoming Investor Conferences
2023-11-14 08:00U:MGTXNews ReleaseMeiraGTx Announces Third Quarter 2023 Financial and Operational Results
2023-10-31 08:02U:MGTXNews ReleaseBestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
2023-10-30 07:30U:MGTXNews ReleaseMeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
2023-10-24 08:30U:MGTXNews ReleaseMeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
2023-08-10 08:00U:MGTXNews ReleaseMeiraGTx Reports Second Quarter 2023 Financial and Operational Results
2023-08-01 09:11U:MGTXNews ReleaseMeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
2023-07-19 08:30U:MGTXNews ReleaseMeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
2023-06-27 07:30U:MGTXNews ReleaseMeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
2023-06-22 16:01U:MGTXNews ReleaseMeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company ¢ € ™s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June
2023-05-16 09:00U:MGTXNews ReleaseMeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
2023-05-11 08:00U:MGTXNews ReleaseMeiraGTx Reports First Quarter 2023 Financial and Operational Results